Welcome to Paid Research Studies




  • Condition:   Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
    Intervention:   Drug: ABBV-176
    Sponsor:   AbbVie
    Recruiting - verified July 2017

  • Conditions:   Adrenocortical Carcinoma;   Peritoneal Carcinomatosis
    Interventions:   Drug: Cisplatin;   Drug: Sodium thiosulfate;   Procedure: Cytoreductive surgery
    Sponsor:   Columbia University
    Not yet recruiting - verified April 2017

  • Conditions:   Paraganglioma;   Gastrointestinal Stromal Tumors;   Carcinoma, Renal Cell;   Renal Neoplasms;   Pheochromocytoma
    Intervention:   Drug: SGI-110 (guadecitabine)
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting - verified April 13, 2017

  • Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukaemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified February 2017

  • Conditions:   Neuroendocrine Tumors;   Carcinoma, Small Cell Lung;   Carcinoma, Large Cell Lung;   Merkel Cell Carcinoma;   Pheochromocytoma;   Paraganglioma;   Thyroid Cancer, Medullary;   Neuroendocrine Carcinoma
    Intervention:   Drug: PEN-221
    Sponsor:   Tarveda Therapeutics
    Recruiting - verified June 2017

  • Conditions:   Adrenal Cortex Carcinoma;   Adult Alveolar Soft Part Sarcoma;   Adult Clear Cell Sarcoma of Soft Parts;   Adult Hepatocellular Carcinoma;   Adult Rhabdomyosarcoma;   Adult Soft Tissue Sarcoma;   Childhood Alveolar Soft Part Sarcoma;   Childhood Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Childhood Hepatocellular Carcinoma;   Childhood Rhabdomyosarcoma;   Childhood Soft Tissue Sarcoma;   Childhood Solid Neoplasm;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adult Hepatocellular Carcinoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Hepatocellular Carcinoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Renal Cell Carcinoma;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Dermoid Cyst;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
    Interventions:   Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified July 2017

  • Condition:   Cushing's Syndrome
    Intervention:   Drug: CORT125134
    Sponsor:   Corcept Therapeutics
    Recruiting - verified June 2017

  • Condition:   Advanced Cancers
    Interventions:   Drug: Pembrolizumab;   Behavioral: Phone Call Follow-Up
    Sponsors:   M.D. Anderson Cancer Center;   Merck Sharp & Dohme Corp.
    Recruiting - verified June 2017

  • Condition:   Adrenocortical Carcinoma
    Intervention:   Drug: Pembrolizumab
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Merck Sharp & Dohme Corp.
    Recruiting - verified May 2017

  • Conditions:   Cushing's Syndrome;   Ectopic Corticotropin Syndrome;   Adrenal Adenoma;   Adrenal Carcinoma;   AIMAH;   PPNAD
    Intervention:   Drug: Osilodrostat
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified July 2017

  • Conditions:   Thyroid Cancer, Medullary;   Carcinoid Tumor;   Pheochromocytoma;   Paraganglioma;   Insulinoma;   Neuroblastoma
    Intervention:   Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
    Sponsor:   British Columbia Cancer Agency
    Available - verified December 2016

  • Conditions:   Adrenal Incidentaloma;   Adrenocortical Carcinoma
    Intervention:  
    Sponsors:   University Medical Center Groningen;   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   VU University Medical Center;   Radboud University;   Leiden University Medical Center;   Maastricht University Medical Center;   UMC Utrecht;   Erasmus Medical Center;   Martini Hospital Groningen;   Canisius-Wilhelmina Hospital;   Diakonessenhuis, Utrecht;   Isala;   Haga Hospital;   St. Antonius Hospital;   Kennemer Gasthuis;   Maxima Medical Center;   Medical Center Alkmaar;   Medical Centre Leeuwarden;   Meander Medical Center;   Medisch Spectrum Twente;   Onze Lieve Vrouwe Gasthuis;   Rijnstate Hospital;   Elisabeth-TweeSteden Ziekenhuis;   Tergooi Hospital;   Vlietland Ziekenhuis;   Scheper Hospital;   Flevo Hospital
    Recruiting - verified June 2017

  • Condition:   Neuroendocrine Tumors
    Interventions:   Drug: Cabozantinib;   Behavioral: Questionnaire
    Sponsors:   M.D. Anderson Cancer Center;   Exelixis
    Recruiting - verified June 2017

  • Conditions:   Adrenocortical Carcinoma;   Adrenal Cancer;   ACC
    Intervention:   Drug: ATR-101
    Sponsor:   Millendo Therapeutics, Inc.
    Recruiting - verified February 2017

  • Condition:   Solid Tumors
    Intervention:   Drug: Avelumab
    Sponsors:   EMD Serono;   Merck KGaA
    Recruiting - verified July 2017

  • Condition:   Adrenocortical Carcinoma
    Intervention:   Drug: MITOTANE
    Sponsor:   University of Turin, Italy
    Recruiting - verified May 2017

  • Conditions:   Adrenal Tumors;   Adrenocortical Carcinoma;   Cushing Syndrome;   Conn Syndrome;   Pheochromocytoma
    Intervention:  
    Sponsors:   University of Wuerzburg;   Deutsche Krebshilfe e.V., Bonn (Germany);   German Federal Ministry of Education and Research
    Recruiting - verified October 2016

  • Condition:   Adrenocortical Carcinoma
    Intervention:  
    Sponsor:   University of Wuerzburg
    Recruiting - verified October 2016

  • Condition:   Adrenocortical Carcinoma
    Intervention:  
    Sponsors:   University of Wuerzburg;   Deutsche Krebshilfe e.V., Bonn (Germany)
    Recruiting - verified October 2016

  • Condition:   Adrenal Gland Neoplasm
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified March 24, 2017